CanBas Past Earnings Performance
Past criteria checks 0/6
CanBas's earnings have been declining at an average annual rate of -20.6%, while the Biotechs industry saw earnings growing at 24.8% annually. Revenues have been declining at an average rate of 46.7% per year.
Key information
-20.6%
Earnings growth rate
1.9%
EPS growth rate
| Biotechs Industry Growth | 31.9% |
| Revenue growth rate | -46.7% |
| Return on equity | -34.1% |
| Net Margin | n/a |
| Next Earnings Update | 10 May 2024 |
Recent past performance updates
Revenue & Expenses BreakdownBeta
How CanBas makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 0 | -1,074 | 205 | 0 |
| 30 Sep 23 | 0 | -1,116 | 196 | 0 |
| 30 Jun 23 | 0 | -1,244 | 184 | 0 |
| 31 Mar 23 | 0 | -983 | 182 | 0 |
| 31 Dec 22 | 0 | -1,059 | 176 | 0 |
| 30 Sep 22 | 0 | -979 | 176 | 0 |
| 30 Jun 22 | 0 | -855 | 175 | 0 |
| 31 Mar 22 | 26 | -733 | 185 | 0 |
| 31 Dec 21 | 53 | -580 | 183 | 0 |
| 30 Sep 21 | 81 | -519 | 182 | 0 |
| 30 Jun 21 | 108 | -531 | 174 | 0 |
| 31 Mar 21 | 110 | -548 | 179 | 0 |
| 31 Dec 20 | 110 | -610 | 176 | 0 |
| 30 Sep 20 | 110 | -637 | 178 | 0 |
| 30 Jun 20 | 110 | -572 | 186 | 0 |
| 31 Mar 20 | 109 | -516 | 184 | 0 |
| 31 Dec 19 | 109 | -571 | 180 | 0 |
| 30 Sep 19 | 109 | -492 | 166 | 0 |
| 30 Jun 19 | 115 | -456 | 161 | 0 |
| 31 Mar 19 | 116 | -486 | 172 | 0 |
| 31 Dec 18 | 116 | -435 | 180 | 0 |
| 30 Sep 18 | 116 | -508 | 189 | 0 |
| 30 Jun 18 | 110 | -532 | 191 | 0 |
| 31 Mar 18 | 109 | -528 | 197 | 0 |
| 31 Dec 17 | 109 | -463 | 193 | 0 |
| 30 Sep 17 | 109 | -415 | 193 | 0 |
| 30 Jun 17 | 109 | -419 | 190 | 0 |
| 31 Mar 17 | 110 | -374 | 196 | 0 |
| 31 Dec 16 | 110 | -485 | 188 | 0 |
| 30 Sep 16 | 107 | -480 | 173 | 0 |
| 30 Jun 16 | 105 | -414 | 167 | 0 |
| 31 Mar 16 | 101 | -384 | 182 | 0 |
| 31 Dec 15 | 99 | -255 | 179 | 0 |
| 30 Sep 15 | 85 | -256 | 182 | 0 |
| 30 Jun 15 | 60 | -266 | 178 | 0 |
| 31 Mar 15 | 36 | -293 | 174 | 0 |
| 31 Dec 14 | 11 | -369 | 177 | 0 |
| 30 Sep 14 | 0 | -372 | 180 | 0 |
| 30 Jun 14 | 0 | -376 | 181 | 0 |
| 31 Mar 14 | 0 | -396 | 167 | 0 |
| 31 Dec 13 | 0 | -417 | 176 | 0 |
| 30 Sep 13 | 0 | -510 | 171 | 0 |
Quality Earnings: 4575 is currently unprofitable.
Growing Profit Margin: 4575 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 4575 is unprofitable, and losses have increased over the past 5 years at a rate of 20.6% per year.
Accelerating Growth: Unable to compare 4575's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 4575 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.9%).
Return on Equity
High ROE: 4575 has a negative Return on Equity (-34.1%), as it is currently unprofitable.